Screening for brain fog: Is the montreal cognitive assessment an effective screening tool for neurocognitive complaints post-COVID-19?

ABSTRACT:

Background

Cognitive complaints are one of the most frequent symptoms reported in post-acute sequelae of COVID-19 (PASC). The Montreal Cognitive Assessment (MoCA) has been used to estimate prevalence of cognitive impairment in many studies of PASC, and is commonly employed as a screening test in this population, however, its validity has not been established.

Objective

To determine the utility of the MoCA to screen for cognitive impairment in PASC.

Methods

Sixty participants underwent neuropsychological, psychiatric, and medical assessments, as well as the Montreal Cognitive Assessment, 6-8 months after acute COVID-19 infection.

Results

The overall sample had a mean score of 26.1 on the MoCA, with approximately one third screening below the cutoff score of 26,

SUBMITTER: Lynch S 

PROVIDER: S-EPMC9359801 | biostudies-literature | 2022 Sep-Oct

REPOSITORIES: biostudies-literature